{"id":213,"date":"2023-02-15T15:54:22","date_gmt":"2023-02-15T15:54:22","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=213"},"modified":"2023-03-15T16:57:54","modified_gmt":"2023-03-15T16:57:54","slug":"pathos","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=213","title":{"rendered":"Pathos"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

The PATHOS trial aims to examine whether reducing the intensity of adjuvant treatment following transoral surgery (transoral laser microsurgery (TLM) or transoral robotic surgery (TORS)) in Human Papillomavirus (HPV) related Oropharyngeal Squamous Cell Cancer (OPSCC) patients will result in improved swallowing outcomes, whilst maintaining local control rates and survival. The trial aims to recruit 1100 patients from UK and international centres until the end 2024.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>2 cases<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>2 cases<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective review of first lateralised and non-lateralised patient<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>CompARE, TORPEdO, BEST OF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact:<\/strong> pathos.enh-tr@nhs.net<\/em> <\/p>\n\n\n\n

Chief investigator: <\/strong>Prof Mererid Evans \/ Prof Terence Jones<\/p>\n\n\n\n

RT Lead: <\/strong>Dr Nachi Palaniappan, Dr Matthew Beasley, Dr Richard Webster<\/em><\/p>\n\n\n\n

Sponsor: <\/strong>Velindre University NHS Trust & Cardiff University,  <\/em>PATHOS@cardiff.ac.uk<\/em><\/a><\/p>\n\n\n\n

Funder: <\/strong>Cancer Research UK<\/p>\n","protected":false},"excerpt":{"rendered":"

Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer Trial summary: […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-213","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=213"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/213\/revisions"}],"predecessor-version":[{"id":344,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/213\/revisions\/344"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}